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Abstract 
Background: The emergence and increase in the incidence of Extended-spectrum beta lactamase (ESBL) 
producing Escherichia coli (E. coli) has become an emerging challenge especially in hospitalized patients with 
urinary tract infection (UTI). The aim of the present study was to survey the frequency of bla CTX-M genotype 
in ESBL producing E. coli isolated from hospitalized patients with urinary tract infection and determination of 
their antibiotic resistance pattern. 
Materials and Methods: A total of 135 E. coli isolates were collected and isolated from patients with UTI. The 
isolates were subjected to confirmatory phenotype tests for the presence of ESBL. 75 E. coli isolates were 
confirmed as ESBL-positive by double disc synergy test. In vitro susceptibility of ESBL isolates to 15 
antimicrobial agents amoxicillin, penicillin, ceftazidime, cefotaxime, cefoxitin, ceftriaxone, cefixime, 
cephalexin, co-trimoxazole, gentamicin, nalidixic acid, ciprofloxacin, nitrofurantoin, amikacin, and imipenem 
was performed by Kirby-Bauer’s Disk diffusion method according to Clinical and Laboratory Standards 
Institute (CLSI, 2012) guideline. PCR method was used to identify bla CTX-M gene in 75 ESBL positive 
strains. 
Results: PCR and sequence analysis showed that 75 (55.5%) isolates produced bla CTX-M genes. In vitro 
susceptibility of ESBL producing E. coli showed that all of them were resistant to amoxicillin and penicillin. 
The rates of resistance to the majority of tested antibiotics varied among 61% to 100 %, with the exception 
of amikacin (14.7%) and imipenem (2.7%). Our results showed that the frequency of bla CTX-M was 
strikingly high (93.3%) in patients with UTI. 
Conclusion: These data confirmed that the frequency of bla CTX-M genes was high among E. coli isolated 
from patients with UTI. The trend of multidrug-resistant profile has been associated with bla CTX-M gene is 
alarming. Therefore, it is very important to establish a routine screening of ESBL in clinical isolates to prevent 
dissemination of resistant isolates in health care settings. 
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Introduction 
Extended-spectrum beta lactamase (ESBL) 
producing Enterobacteriaceae were reported in 
Europe and subsequently United States in the early 
1980s. They have been detected in Klebsiella species 
and later in Escherichia coli (E. coli), Pseudomonas 
aeruginosa and Serratia marcescens and other 
genera of the Enterobacteriaceae family
1
. The 
emergence of ESBL, as an important cause of 
transferable multidrug resistance in gram-negative 
bacteria, particularly in E. coli is a global health 
problem since 1995
2,3
. ESBLs are a heterogeneous 
group of enzymes that confer resistance to 3 and 4 
generation of cephalosporins and monobactams
4
. The 
production of beta lactamase as a predominant cause 
of resistance to beta lactam antibiotics among 
bacteria is mostly mediated by acquisition of beta 
lactamase genes which is located on mobile genetic 
elements such as plasmids or transposons. According 
to the scheme of Ambler et al., ESBLs are grouped 
into four classes A, B, C and D on the basis of their 
amino acid sequences
5
. In comparison of other 
classes, classes A and C are the most common 
classes. Class A ESBLs hydrolyzes oxyimino-
cephalosporins and aztreonam and generally 




At present, there are more than 400 ESBLs that have 
been clustered into nine different structural and 
evolutionary families based on amino acid sequence
6
. 
The most ESBLs can be divided into 3 genotypes: 
temoneira (TEM), sulfhydryl variable (SHV) and 
cefotaximase (CTX-M)
6,7
. CTX-M, TEM and SHV 
are class A ESBLs
1,4,6
.  
The CTX-M beta lactamases are the most widespread 
enzymes. They were initially reported in the second 
half of 1980s. Rate of their disseminations in both 
over wide geographic areas and among a wide range 
of clinical bacteria has rapidly increased since 1995
8
. 
Several investigators believed that CTX-M ESBL 
was dominant type in east Asia since it has appeared 
or caused outbreaks in many countries
4,9
.  
Before 2000, the predominant ESBL genotypes were 
TEM and SHV variants which were produced by 
Klebsiella spp., Enterobacter spp., and E. coli but 
during the past few years, the nature of ESBL 
dissemination has changed and E. coli strains 
expressing CTX-M have presently replaced TEM and 
SHV as the most common type of ESBLs
10
.  
Moreover, CTX-M-type ESBLs have emerged within 
the community, particularly among E. coli and K. 
pneumoniae isolated from urinary tract infections 
(UTIs), with a widespread prevalence and multidrug 
resistance in many worldwide countries
4
.  
The emergence of ESBL as an important cause of 
transferable multidrug resistance in gram-negative 
bacteria, particularly Escherichia coli is now a serious 
problem of public health worldwide. However, there 
are still few reports on the prevalence of ESBL 
producing E. coli in the hospitals of Iran. With this 
background, we investigated the prevalent ESBL type 
of E. coli isolated from patients with UTI and then 
determination of their pattern of antimicrobial 
resistance to antimicrobial agents had commonly been 
used. 
Methods 
Bacterial isolates: A total of 75 ESBL-producing E. 
coli were recovered from 135 patients with UTI during 
August 2013 to April 2014. Urine samples were 
obtained from a midstream into standardized, sterile a 
period of 9 containers and delivered to the laboratory 
within 2 hours after had been collected. Identification 
was done based on culture characteristics, gram stain 
and routine standard biochemical tests. Colony count 
method was done according to surface streak 
procedure by using calibrated loops. The cultured 
plates were incubated in aerobic conditions at 37°C for 
24-48 hours. The result of equal or more than 10
5
 
CFU/mL was considered as positive UTI and a less 
than 10
2





 CFU/ml was repeated
11
. 
Screening ESBL producing isolates by phenotypic 
method: ESBL production was confirmed 
phenotypically by double disc synergy test (DDST) 
according to the Clinical and Laboratory Standards 
Institute (CLSI) criteria for ESBL screening
12
. 
According to the CLSI protocol, DDST was done by 
using cefotaxime (30 µg) and ceftazidime (30 µg) with 
and without clavulanic acid (10 µg). Discs were placed 
25 mm apart from each other on Muller-Hinton agar 
(MHA, Oxoid, UK) plate inoculated with 0.5 
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McFarland suspension of the tested isolates. An 
increase of equal or more than 5 mm in zone 
diameter for either antimicrobial agent tested with 
clavulanic acid versus its zone when tested without 
clavulanic acid indicated the presence of ESBL
13
. E. 
coli ATCC 25922 was used as control strain. 
Antimicrobial susceptibility testing: The 
susceptibility testing of the ESBL-producing E. coli 
isolations to antibiotics were examined by Kirby-
Bauer’s disk diffusion method according interpretive 
criteria recommended by CLSI guidelines. Antibiotic 
susceptibility test was carried out on Mueller Hinton 
agar (MHA, Oxoid, UK)  to the fallowing agents: 
Gentamicin (GEN 10 µg), ciprofloxacin (CIP 5 µg), 
amikacin (AK 30 µg), ceftazidime (CZX 30 µg), 
imipenem (IMP 10 µg), cefotaxime (CTX 30µg), 
cefoxitin (CX 30 µg), cephalexin (CN 30 µg), co-
trimoxazole (COT 25 µg), amoxicillin (AMX 30 µg), 
penicillin (P 10 µg), nalidixic acid (NA 30 µg), 
nitrofurantoin (NIT 300 µg), ceftriaxone (CTR 30 µg) 
and cefixime (CFM 5 µg). Antibiotic disks used in this 
research were supplied by HiMedia Laboratories Pvt, 
Ltd., Mumbai, India.  
Briefly, the bacterial suspension equivalent to a no. 0.5 
McFarland standard was inoculated on Mueller-Hinton 
agar (Oxoid, UK) and then antibiotics were placed at 
distances of 22 mm apart. After 24h incubation at 37ºC, 
diameter of inhibition zones was read and their results 
were interpreted as susceptible, intermediate, and 
resistant. E. coli ATCC 25922 was used as control 
strian. Samples confirmed as E. coli were stored in 
Tryptic Soy Broth (TSB; Merck, Germany) containing 
20% glycerol at -70°C and were subjected to further 
molecular identification. 
DNA extraction and identification of bla CTX-M 
gene by PCR: Confirmed ESBL producing isolates 
with the combination disk diffusion test were 
characterized for the presence of CTX-M beta 
lactamase. Hence, DNA was extracted from bacterial 
cells by using QIAamp DNA isolation columns 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s procedure. The concentration of 
extracted DNA was assessed by specterophotometer. 
The PCR reactions for detection bla CTX-M genes 
were done within a total volume of 25 µL. The 
mixture of reaction contained 1x buffer (10 mM Tris-
HCl, 50 mM KCl), 0.2M of each deoxynucleoside 
triphosphate, 1 mM MgCl2, 0.5 M of forward and 
reverse primers of CTX-M genes, and 1 Unit of 
Takara Taq (Takara Shuzo Co., Ltd., Shiga, Japan). 
The Primer sequences, which were used for detection 
of bla CTX-M genes in this study, were as follows: 
CTX-M-F (5´-ACGCTGTTGTTAGGAAGTG-3´) and 
CTX-M-R (5´-TTGAGGCTGGGTGAAGT-3´). PCR 
conditions for amplification of 857 bp fragment of the 
CTX-M gene was carried out by the thermocycler (AG 
22331; Eppendorf, Hamburg, Germany) as follows: 
initial denaturation at 94°C for 5 min, denaturation at 
94°C for 1 min, annealing at 58°C for 30 second, and 
extension at 72°C for 1 min, was repeated for 36 
cycles; a final extension at 72°C for 10 min. 
Agarose gel electrophoresis was done a 1.2% agarose 
 
 
Figure 1. The susceptibly pattern of 75 ESBL producing E. coli isolates to 15 antimicrobial agents 
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gel at 80V for 2 hours. After electrophoresis 
fragments were stained by Ethidium Bromide, and 
then visualized with ultraviolet light. PCR products 
were sequenced and nucleotide sequences were 
compared with sequences in the GenBank and 
EMBL databases using the BLASTN local alignment 
search tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Statistical analysis: The results were analyzed using 
with SPSS software for Windows, version 17.0 
(SPSS Inc., Chicago, IL). 
Results 
In this study, from the 135 E. coli isolates, 75 
(55.5%) were ESBL producer. Eighty percent (n=60) 
of the positive patients were female and 20% (n=15) 
were male. The average age was 49.6 years old and 
patient’s age ranged from 2 to 73 years old. Patients 
were classified in 4 different age groups. The age 
distribution was 16% for  ≤20 year, 14.6% for 20-35 
years, 33.3% for 36 to 60 years, and 36% for ≥60 
years. The results of disk-diffusion antimicrobial 
susceptibility testing revealed the full resistance to 
amoxicillin and penicillin and high level of resistance 
to other tested antimicrobial agents. The majority of 
isolates were resistance to cefotaxime 98.7%, 
cefixime 97.3%, ceftriaxone 94.7%, nitrofurantoin 
92%, ceftazidime 81.3%, co-trimoxazole 80%, 
ciprofloxacin  77.3%, cefoxitin 70.7%, gentamicin 
65.3%, cephalexin 64%; nalidixic acid 61.3%. The 
rates of resistance to the majority of tested antibiotics 
varied from 61% to 100 %, with the exception of 
amikacin (14.7%) and imipenem (2.7%). None of 
isolates were sensitive to all antibiotics. Only one 
isolate was resistant to all of tested antibiotic. 
Antimicrobial susceptibility pattern of the ESBL-
 
 
Figure 2. Lane M, ladder (Fermentas, UK); lane 1, the 857 bp 
PCR product of bla CTX-M; lan 2 positive control (K. pneumonia 
ATCC 700603); lan 3 negative control (E. coli ATCC 25922) 
 
Table 1: Multi- drug resistance pattern of 75 ESBL producing E. coli isolates 
Resistant patterns  
Antibiotics 
No. 
Total number of resistant 
isolates (%) 
AMX, P, CTX 
AMX, P, CFM 
AMX, P, CTR 
AMX, P, NIT 
3 10 (13.3) 
AMX, P, CTX, CFM 
AMX, P, CTX, AK 
AMX, P, CTX, NIT 
AMX, P, CTX, CX 
AMX, P, CTX, CZX 
4 8 (10.7) 
AMX, P, CTX, CFM, GEN 
AMX, P, CTX, CFM, AK 
5 12 (16) 
AMX, P, CTX, CFM, CTR, NIT 
AMX, P, CTX, CFM, CTR, COT 
AMX, P, CTX, CFM, CTR, AK 
6 11(14.7) 
AMX, P, CTX, CFM, CTR, CN, COT 
AMX, P, CTX, CFM, CTR, CN, AK 
7 
34 (45.3) 
AMX, P, CTX, CFM, CTR, CX, NIT, COT, CZX 9 
AMX, P, CTX, CFM, CTR, CX, NIT, COT, CZX, IMP 10 
AMX, P, CTX, CFM, CTR, CX, CIP, NIT, COT, NA, GEN  11 
AMX, P, CTX, CFM, CTR, CX, CN, CZX, CIP, NA, COT, GEN, NIT, AK, IMP 15 
GEN: Gentamicin, CIP: ciprofloxacin, AK: amikacin, CZX: ceftazidime, IMP: imipenem, CTX: cefotaxime, CX: cefoxitin, CN: cephalexin, COT: 
co-trimoxazole, AMX: amoxicillin, P: penicillin, NA: nalidixic acid, NIT: nitrofurantoin, CTR: ceftriaxone and CFM: cefixime 
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producing strains to 15 tested antibiotics are shown 
in figure 1. 
Multi drug resistance (MDR) was defined as resistance 
to three or more classes of antibiotics
14
. MDR was 
observed in all of isolates. Frequencies of MDR to 
three, four, five, six and more antibiotics were 10 
(13.3%), 8 (10.7%), 12 (16%), 11 (14.7%) and 34 
(45.3%). Of the 75 MDR isolates, the most prevalent 
patterns were resistance to more than 6 (n=34; 45.3%), 
followed by 5 (n=12; 16%) and 6 (n=11; 14.7%) of 
antimicrobial agents. The predominant resistance 
profile among our isolates was included resistance to 9 
antibiotics amoxicillin, penicillin, cefotaxime, 
ceftriaxone, cefexime, nitrofurantoin, co-trimoxazole, 
ceftazidime and cefoxitin (20%), followed by resistance 
to 5 antibiotics amoxicillin, penicillin, cefotaxime, 
gentamicin and cefexime (13.3%). 
PCR detection of bla CTX-M gene in ESBL producing 
E. coli showed that 70 out of 75 (93.3%) isolates were 
positive for bla CTX-M gene. 
Discussion 
The spread of ESBL-producing bacteria is a 
significant public health threat due to the consuming 
limitation of therapeutic options for infections. 
Dissemination of ESBL-producing bacteria could be 
attributed to the presence of multiple risk factors 
such as inappropriate use of broad-spectrum 
antimicrobials, inappropriate prescription, long 
duration of hospital stay and transfer of ESBL genes 
by transposable elements such as plasmid and 
integron in health care settings
15
.  
Our findings showed Females had a higher rate of 
isolation of ESBL producing E. coli (80%) that is in 
agreement with findings of other investigators
16
. In 
the present study, the most infected age group with 
ESBL-producing E. coli was ≥60 years (36%). Our 
results, regarding the age of the patients, is in 
agreement with recent data that states aging is a risk 
factor for beta lactamase-mediated resistance in 
patients infected with enterobacteriaceae
17
.  
In recent years, the spread of ESBL producing E. coli 
isolates have been reported threateningly in many 
regions of the world
18,19
. Several studies exhibited 
that the prevalence of ESBL-producing bacteria is a 
serious problem of public worldwide health and their 
distribution can be vary according to geographic 
region, country and studied institution
20
. The present 
study showed that out of 135 tested samples 75 
(55.5%) were ESBL positive. Our results were lower 




















, Saudi Arabia 
(30.6%)
26
. These differences could be attributed to 
type and volume of samples, duration of study and 
drug regimens in different geographical regions. 
The susceptibility pattern of ESBL producer’s isolates 
to antibiotics has decreased recent years in many 
countries
10
. The results obtained by this study revealed 
that all of ESBL producer’s isolates were resistant to 
amoxicillin and penicillin. The lowest rates of 
resistance in ESBL-producing isolates were observed 
for imipenem (2.7%) and amikacin (14.7%). These 
resistance profiles were in accordance with other 
studies
27
. In present study, an alarming rate of 
decrease in the susceptibility not only to beta lactam 
but also to different antibiotic families including 
trimethoprim/sulfamethoxazole, sulfamethoxazole -
ones, quinolones and aminoglycosides were seen. A 
possible reason of high resistance in our study might 
be contributed to the presence of ESBL in these 
strains. Overall, this is an alarm for clinicians that 
consumption and prescription of these antibiotics must 
be changed. 
Due to carrying of multi resistant genes by plasmid 
and integron and also their readily transfer between 
and within microbial pathogens, bacteria with multiple 
resistances to antibiotics are widely distributed in 
hospitals and increasingly being isolated from 
community
12
. Multiple resistances to antibiotics are 
frequently observed among ESBL producers hence the 
presence of an ESBL is a good marker of the MDR 
phenotype and resistance to newer beta lactam 
antibiotics
28
. It is important to note that all of isolates 
showed MDR phenotype. The prevalence of MDR is 
increasing throughout the world
1,4
. In this respect, 
several studies expressed that the existence of MDR 
phenotype among E. coli isolates have lower 
frequencies in Europe and United States than in Asia 
and Africa. In a study done in Sudan in 2012, Ibrahim 
et al. showed that from 232 E. coli isolates, 214 
(92.2%) isolates were MDR
21
. In compare to studies 
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 a high prevalence of MDR were seen 
in our study. This high prevalence of MDR in our 
study could be due to differences in the type of 
samples, Population investigated, poor health 
condition in hospitals and the social and geological 
factors. 
The incidence of CTX-M among plasmid-mediated 
ESBL strains is continuously increasing and bla 
CTX-M has already become the most common ESBL 
gene
20
. As expected, the frequency of CTX-M 
enzymes in our study was very high that is in 
accordance with recent data. Vaida et al., studied 175 
non-duplicate clinical isolates (62 E. coli and 113 K. 
pneumoniae) showed that 47 (76%) E. coli and 98 
(87%) K. pneumoniae isolates were identified as 
ESBL producers and CTX-M-encoding genes were 
found in the majority of E. coli (96%) and K. 




In Portugal, Mendonca et al. (2007) have studied 180 
of E. coli recovered in various Portuguese hospitals 
from cases of community-acquired and nosocomial 
infections, found that CTX-M producer’s isolates 
were prevalent among community-acquired 
infections (56%), urinary tract infections (76%), and 
patients ≥60 years old (76%)
32
. 
In a nationwide study of ESBL-producing E. coli 
from 10 different centers in Turkey between 2011 
and 2012, the presence of the three common ESBL 
genes: TEM, CTX-M and SHV using PCR method, 
were evaluated. Then, they found that CTX-M1 
group is the most common type of class A beta 




These higher rates of CTX-M among our isolates 
may be associated with high mobilization of the 
encoding genes so that Barlow et al. (2008) reported 
increased tenfold in movement of bla CTX-M genes 





Currently, CTX-M-producing E. coli strains are 
serious problem of public health in Iran which may 
be related to free access, misuse and abuse of third 
generation cephalosporins, especially cefotaxime. 
Our study suggests that E. coli strains carrying bla 
CTX-M genes are widespread in Iran. With regards 
ESBL mediated resistance to wide range of 
antimicrobial classes; it is worthwhile that routine 
screening of ESBL in clinical isolates carried out in 
order to prevent dissemination of resistant isolates in 
our hospitals. 
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